Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

What does the future of clinical trials and evidence-based medicine look like?

What does the future of clinical trials and evidence-based medicine look like?

The efficacy of low-dose fluvoxamine compared with placebo for treating mild to moderate COVID-19 in the US

The efficacy of low-dose fluvoxamine compared with placebo for treating mild to moderate COVID-19 in the US

The "Great Escape" by SARS-CoV-2 XBB.1

The "Great Escape" by SARS-CoV-2 XBB.1

An in-depth meta-analysis highlights COVID-19's pregnancy dangers

An in-depth meta-analysis highlights COVID-19's pregnancy dangers

Future COVID-19 control will require vaccines that induce better mucosal immunity

Future COVID-19 control will require vaccines that induce better mucosal immunity

On four flights out of China in December, 22% of passengers were SARS-CoV-2 positive

On four flights out of China in December, 22% of passengers were SARS-CoV-2 positive

What are the major findings of long COVID research?

What are the major findings of long COVID research?

Exploring bioinformatics approach for evaluating binding affinities of probable COVID-19 therapeutic decoys

Exploring bioinformatics approach for evaluating binding affinities of probable COVID-19 therapeutic decoys

S. aureus enhances replication of SARS-CoV-2 in vitro through the bacterial iron-regulated surface determinant protein A

S. aureus enhances replication of SARS-CoV-2 in vitro through the bacterial iron-regulated surface determinant protein A

Could drinking tea help manage COVID-19?

Could drinking tea help manage COVID-19?

Researchers identify inhibitors of the SARS-CoV-2 Nsp14 N7-methyltransferase

Researchers identify inhibitors of the SARS-CoV-2 Nsp14 N7-methyltransferase

Preclinical study shows the therapeutic value of kinetin against SARS-CoV-2

Preclinical study shows the therapeutic value of kinetin against SARS-CoV-2

The impact of cross-reactive immunity on the probability that a newly introduced SARS-CoV-2 variant will invade the host population

The impact of cross-reactive immunity on the probability that a newly introduced SARS-CoV-2 variant will invade the host population

Study finds non-Omicron breakthrough infections elicit robust cross-neutralizing activity against Omicron variants across the antigenic barrier

Study finds non-Omicron breakthrough infections elicit robust cross-neutralizing activity against Omicron variants across the antigenic barrier

Overall patterns of SARS-CoV-2 caused by variants of concern among children and adolescents

Overall patterns of SARS-CoV-2 caused by variants of concern among children and adolescents

Researchers report that vectored expression of a high-affinity ACE2 microbody protein establishes a high degree of protection from SARS-CoV-2

Researchers report that vectored expression of a high-affinity ACE2 microbody protein establishes a high degree of protection from SARS-CoV-2

Intranasal mRNA-lipid nanoparticle vaccines elicit significant protection against SARS-CoV-2 in hamsters

Intranasal mRNA-lipid nanoparticle vaccines elicit significant protection against SARS-CoV-2 in hamsters

The long-term clinical outcomes of SARS-CoV-2 infection in people with mild disease in Israel

The long-term clinical outcomes of SARS-CoV-2 infection in people with mild disease in Israel

COVID-19 convalescent plasma transfusions significantly reduced mortality rates among hospitalized SARS-CoV-2 patients

COVID-19 convalescent plasma transfusions significantly reduced mortality rates among hospitalized SARS-CoV-2 patients

What is the effectiveness of a multivalent exosome-based COVID-19 vaccine?

What is the effectiveness of a multivalent exosome-based COVID-19 vaccine?

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.